Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

alcohol dependence

  • Home
  • alcohol dependence
Efficacy and Safety of ALM-003 Digital Therapeutic in Alcohol Dependence: A Multicenter Open-Label Randomized Controlled Trial
Posted inAI news Psychiatry Specialties

Efficacy and Safety of ALM-003 Digital Therapeutic in Alcohol Dependence: A Multicenter Open-Label Randomized Controlled Trial

Posted by MedXY By MedXY 08/20/2025
This review synthesizes evidence from a multicenter RCT showing ALM-003 digital therapeutic reduces heavy drinking days significantly in alcohol-dependent individuals at high risk, with an excellent safety profile.
Read More
  • Most Patients With Uncertain Response After Neoadjuvant Chemoradiotherapy for Esophageal Cancer Still Harbor Residual Disease
  • Molecular and Spatial Differences in the Tumor Microenvironment of High-Grade Serous Ovarian Cancer With Short vs Long-Term Survival
  • Proteinuria in Preeclampsia and Long-Term Risk of Maternal Kidney and Cardiovascular Disease
  • Does the order of ablation of vein-to-vein placental connections during fetoscopic laser photocoagulation affect outcomes in twin-twin transfusion syndrome?
  • Prepregnancy Insulin Resistance and Fertility Outcomes in Women With PCOS
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in